Inhalation products

Siegfried offers a broad portfolio of active pharmaceutical ingredients including controlled substances, focused on anesthetics, analgesics, decongestants, addiction treatment, and a variety of other therapeutic indications. In addition, we offer pharma grade caffeine for use in pharmaceutical and nutritio...

We are experts in process development and manufacturing of exclusive active pharmaceutical ingredients and intermediates.

Your most trusted partner for exclusive synthesis:- More than 150 years experience in process development and production of customized APIs
- Secure and relia...

Our team has multiple decades of experience offering a wide range of services from development to manufacturing at the highest level of quality compliance. Our technologies include dry and wet granulation processing, blending, capsule filling, tableting, coating, blistering and bottling.

We are ...

We are your expert in sterile and aseptic manufacturing, where quality is paramount.
Your most trusted partner for sterile and aseptic fill & finish:
- Extensive knowledge and experience in process and analytical development
- Unbeatable speed to market, without compromising on quality
- ...

Siegfried is your expert in ophthalmic formulations with outstanding manufacturing and packaging capabilities. 

Your most trusted partner for ophthalmics:
- Dedicated Development Center offering development and scale up services
- 95+ years experience asa reliable ophthalmic partner
- ...

Our experienced formulation development teams support commercial development and manufacturing strategies across a wide range of drug programs.
Your most trusted partner for oral solids:
- Extensive knowledge in highly potent APIs
- Resilient and reliable supply chains supported by our global ne...

In our packed out content sessions at CPHI Barcelona this year we focus on some of the hottest topics coming up in the pharma industry, with each track sponsored by a leading expert in the field. 

Highly Potent APIs are a rapidly growing segment of the global pharmaceutical industry, and they are acquiring a significant relevance into the development space. The importance to understand the challenges around development of High Potency Oral solids formulations, are the key to ensure a right scale-up and launch Risk-based approach: measuring the risk, not the hazard Challenges for High potency products handling. Importance of select the adequate partner Development of secure and scalable process in high containment environment

Hameln plant which provides fill and finish for Pfizer-BioNTech COVID-19 shot should be fully operational within the week, CDMO says

The Covid-19 Pandemic forced us to learn new ways of collaborating and innovating to solve a global crisis - what can we learn and leverage from this experience as we adapt to a 'new normal'?
Amazing scientific development and break-throughs are evolving faster than ever, with new advanced treatment options for patients being developed at unprecedented speed. All of us involved in manufacturing and supply need to rethink how we collaborate, deliver medicines and learn faster.
No one company can solve this alone - requiring us to collaborate, innovate and learn in new ways. What does this change really mean for us? Welcome to engage in a discussion, sharing case study data and recent insights in the middle of an industry learning journey.

Though viral vectors are used extensively in cell and gene therapy, the challenges of manufacturing such complex biologics at industrial scale is still a limitation to its broader use.
Dr. Ayuso will speak about how upstream and downstream process optimization using design of experiments (DOE), a platform approach and end-to-end capabilities can tackle manufacturing challenges and help to expedite drug development.

Join Asklepios BioPharmaceutical's former CEO Shelia Ann Mikhail, where she will Set the Scene for the latest innovations and developments affecting the Biomanufacturing Landscape

Ensuring quality and compliance in bio-manufacturing Closing gaps in development data prior to the first GMP production Adjusting manufacturing processes throughout the course of a site-to-site transfer Fulfilling special requirements on container closure systems for biologics Transferring analytical methods for drug products and drug substances

The Covid-19 Pandemic forced us to learn new ways of collaborating and innovating to solve a global crisis - what can we learn and leverage from this experience as we adapt to a new normal? Amazing scientific development and break-throughs are evolving faster than ever, with new advanced treatment options for patients being developed at unprecedented speed. All of us involved in manufacturing and supply need to rethink how we collaborate, deliver medicines and learn faster.
No one company can solve this alone - requiring us to collaborate, innovate and learn in new ways. What does this change really mean for us? Welcome to engage in a discussion, sharing case study data and recent insights in the middle of an industry learning journey.

Manufacturers face unique quality challenges that can hinder progress. In this session, discover quality challenges in Cell and Gene Therapy (CGT) and learn common practices for overcoming them:
Where are all the approvals? Understanding unique manufacturing challenges for Autologous Cell Therapies How does development by design, quality by design, and Cell Therapy COGs converge in this new space? Creating a Cell Therapy technology roadmap to address challenges and drive speed-to-market